Cargando…

Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009–2018

BACKGROUND: Although use of buprenorphine for treating opioid use disorder increased over the past decade, buprenorphine utilization remains limited in lower-income and rural areas. We examine how the Affordable Care Act Medicaid expansion influenced buprenorphine initiation rates by county income a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golan, Olivia K., Sheng, Flora, Dick, Andrew W., Sorbero, Mark, Whitaker, Daniel J., Andraka-Christou, Barbara, Pigott, Therese, Gordon, Adam J., Stein, Bradley D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Full Length Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590758/ https://www.ncbi.nlm.nih.gov/pubmed/37876376 http://dx.doi.org/10.1016/j.dadr.2023.100193

Ejemplares similares

Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021
por: del Pozo, Brandon, et al.
Publicado: (2023)

Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment
por: Stein, Bradley D., et al.
Publicado: (2023)

Analysis of US County Characteristics and Clinicians With Waivers to Prescribe Buprenorphine After Changes in Federal Education Requirements
por: Nguyen, Thuy, et al.
Publicado: (2022)

Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention
por: Stein, Bradley D., et al.
Publicado: (2022)

Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims
por: Xu, Kevin Y, et al.
Publicado: (2023)

Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants
por: Andraka-Christou, Barbara, et al.
Publicado: (2022)

Medicaid expansion and opioid supply policies to address the opioid overdose crisis
por: Shakya, Shishir, et al.
Publicado: (2022)

Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021
por: Nguyen, Thuy D., et al.
Publicado: (2022)

Medicaid expansion in Oregon and postpartum healthcare among people with and without prenatal substance use disorder()
por: Haight, Sarah C., et al.
Publicado: (2022)

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion
por: Saloner, Brendan, et al.
Publicado: (2018)

Pharmacy Participation and Claim Characteristics in the Wisconsin Medicaid Pharmaceutical Care Program from 1996 to 2007
por: Look, Kevin A., et al.
Publicado: (2012)

Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort
por: Wang, Xi, et al.
Publicado: (2023)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements
por: Nguemeni Tiako, Max Jordan, et al.
Publicado: (2023)

Medicaid Expansion’s Spillover to the Criminal Justice System: Evidence from Six Urban Counties
por: FRY, CARRIE E., et al.
Publicado: (2020)

Healthcare Utilization in the Postpartum Period Among Illinois Women with Medicaid Paid Claims for Delivery, 2009–2010
por: Rankin, Kristin M., et al.
Publicado: (2016)

Emergency-department initiated buprenorphine: Impact on quality of life
por: Carroll, Caleb, et al.
Publicado: (2023)

444. County-level COVID-19 Case Fatality Rate in Medicaid Expansion States Compared to Non-Expansion States
por: El-Nahal, Walid, et al.
Publicado: (2021)

COVID‐19‐related Medicaid enrollment in Medicaid expansion and non‐expansion states
por: Benitez, Joseph A., et al.
Publicado: (2022)

The Impact of Medicaid Expansion on Medicaid Focused Insurers in California
por: McCue, Michael J.
Publicado: (2015)

The introduction of a novel formulation of buprenorphine into organized health systems()()
por: Mullen, William, et al.
Publicado: (2022)

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
por: Reed, Megan K, et al.
Publicado: (2022)

Association of State Medicaid Expansion With Rate of Uninsured Hospitalizations for Major Cardiovascular Events, 2009-2014
por: Akhabue, Ehimare, et al.
Publicado: (2018)

Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use
por: Winstanley, Erin L., et al.
Publicado: (2022)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
por: Christine, Paul J., et al.
Publicado: (2023)

Assessment of Rates of Child Maltreatment in States With Medicaid Expansion vs States Without Medicaid Expansion
por: Brown, Emily C. B., et al.
Publicado: (2019)

Can Medicaid be a Solution to the Problem? Underinsurance in Medicaid Expansion Versus Non-Expansion States
por: Izguttinov, Aniyar, et al.
Publicado: (2023)

Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019
por: Andraka-Christou, Barbara, et al.
Publicado: (2023)

A national survey of state laws regarding medications for opioid use disorder in problem-solving courts
por: Andraka-Christou, Barbara, et al.
Publicado: (2022)

Changes in Buprenorphine Prescribing to Medicaid Beneficiaries During the First Year of the COVID-19 Pandemic
por: Dowd, William N., et al.
Publicado: (2022)

An analysis of patterns of distribution of buprenorphine in the United States using ARCOS, Medicaid, and Medicare databases
por: Hsu, Zhi‐Shan, et al.
Publicado: (2023)

State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
por: Silwal, Anita, et al.
Publicado: (2023)

Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US
por: Weiner, Scott G., et al.
Publicado: (2023)

Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program
por: Rowe, Christopher L., et al.
Publicado: (2022)

The Impact of Medicaid Expansion on Diabetes Management
por: Lee, Jusung, et al.
Publicado: (2020)

Changes in buprenorphine visits in frontier and remote locations: Effects of the SARS-CoV-2 pandemic
por: McFadden, Lisa M.
Publicado: (2023)

Psychiatric comorbidities and their treatment predict buprenorphine continuation among postpartum people with opioid use disorder
por: Shadowen, Hannah, et al.
Publicado: (2022)

Association between median household income, state Medicaid expansion status, and COVID-19 outcomes across US counties
por: Apenyo, Tsikata, et al.
Publicado: (2022)

State Medicaid Pharmacy Payments and Their Relation to Estimated Costs
por: Adams, E. Kathleen, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_f2dc0u1183iq0p2v68rcmonn23